Wedbush Securities’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19.1M Buy
88,002
+7,465
+9% +$1.66M 0.56% 24
2025
Q4
$18.4M Buy
80,537
+2,587
+3% +$589K 0.54% 26
2025
Q3
$18M Buy
77,950
+747
+1% +$152K 0.59% 23
2025
Q2
$14.3M Sell
77,203
-5,829
-7% -$1.08M 0.5% 27
2025
Q1
$17.4M Sell
83,032
-7,200
-8% -$1.4M 0.64% 21
2024
Q4
$16M Buy
90,232
+198
+0.2% +$36.4K 0.57% 21
2024
Q3
$17.8M Sell
90,034
-11,759
-12% -$2.19M 0.66% 19
2024
Q2
$17.5M Buy
101,793
+4,165
+4% +$690K 0.62% 19
2024
Q1
$17.8M Buy
97,628
+4,484
+5% +$773K 0.66% 19
2023
Q4
$14.4M Sell
93,144
-4,978
-5% -$726K 0.64% 20
2023
Q3
$14.6M Buy
98,122
+2,458
+3% +$361K 0.73% 17
2023
Q2
$12.9M Sell
95,664
-17,229
-15% -$2.53M 0.61% 20
2023
Q1
$18M Sell
112,893
-170
-0.2% -$26K 0.9% 12
2022
Q4
$18.3M Buy
113,063
+805
+0.7% +$123K 1% 12
2022
Q3
$15.1M Buy
112,258
+2,068
+2% +$297K 0.85% 15
2022
Q2
$16.9M Sell
110,190
-1,769
-2% -$270K 0.92% 10
2022
Q1
$18.1M Sell
111,959
-5,401
-5% -$785K 0.83% 13
2021
Q4
$15.9M Buy
117,360
+2,115
+2% +$250K 0.68% 15
2021
Q3
$12.4M Buy
115,245
+2,911
+3% +$333K 0.59% 22
2021
Q2
$12.7M Buy
112,334
+1,303
+1% +$147K 0.6% 22
2021
Q1
$12M Buy
111,031
+14,438
+15% +$1.54M 0.67% 17
2020
Q4
$10.3M Buy
96,593
+5,781
+6% +$556K 0.91% 13
2020
Q3
$7.95M Buy
90,812
+1,252
+1% +$118K 0.76% 17
2020
Q2
$8.79M Buy
89,560
+11,754
+15% +$1.03M 0.83% 13
2020
Q1
$5.93M Buy
77,806
+1,143
+1% +$97.4K 0.71% 21
2019
Q4
$6.79M Buy
76,663
+2,615
+4% +$217K 0.6% 25
2019
Q3
$5.61M Buy
74,048
+10,183
+16% +$698K 0.55% 27
2019
Q2
$4.64M Buy
63,865
+3,100
+5% +$244K 0.47% 38
2019
Q1
$4.9M Sell
60,765
-11,937
-16% -$977K 0.53% 32
2018
Q4
$6.7M Buy
72,702
+2,300
+3% +$202K 0.86% 18
2018
Q3
$6.66M Buy
70,402
+782
+1% +$74.2K 0.76% 19
2018
Q2
$6.45M Buy
69,620
+3,960
+6% +$387K 0.8% 16
2018
Q1
$6.21M Sell
65,660
-529
-0.8% -$58.1K 0.81% 16
2017
Q4
$6.4M Sell
66,189
-7,984
-11% -$752K 0.78% 17
2017
Q3
$6.59M Sell
74,173
-3,838
-5% -$292K 0.86% 17
2017
Q2
$5.66M Buy
78,011
+3,526
+5% +$237K 0.73% 19
2017
Q1
$4.85M Sell
74,485
-1,901
-2% -$120K 0.66% 21
2016
Q4
$4.78M Sell
76,386
-11,756
-13% -$718K 0.7% 20
2016
Q3
$5.56M Buy
88,142
+13,635
+18% +$883K 0.83% 13
2016
Q2
$4.61M Buy
74,507
+6,537
+10% +$398K 0.76% 16
2016
Q1
$3.88M Buy
67,970
+9,799
+17% +$546K 0.67% 22
2015
Q4
$3.45M Buy
58,171
+11,976
+26% +$690K 0.62% 23
2015
Q3
$2.51M Buy
46,195
+7,086
+18% +$461K 0.5% 30
2015
Q2
$2.63M Buy
39,109
+10,353
+36% +$676K 0.48% 29
2015
Q1
$1.68M Buy
28,756
+5,761
+25% +$348K 0.29% 77
2014
Q4
$1.5M Buy
22,995
+1,335
+6% +$84.2K 0.23% 89
2014
Q3
$1.25M Buy
21,660
+3,008
+16% +$167K 0.19% 102
2014
Q2
$1.05M Sell
18,652
-1,256
-6% -$65.9K 0.17% 122
2014
Q1
$1.02M Buy
19,908
+849
+4% +$42.9K 0.18% 129
2013
Q4
$1.01M Sell
19,059
-411
-2% -$20.2K 0.24% 105
2013
Q3
$871K Buy
19,470
+50
+0.3% +$2.22K 0.23% 113
2013
Q2
$803K Buy
+19,420
New +$849K 0.22% 115

Other funds holding ABBV

Wedbush Securities's ABBV Position: Q1 2026 in Review

Wedbush Securities increased its AbbVie (ABBV) stake by 9.3% in Q1 2026, buying an estimated $1.66M and bringing the position to 88,002 shares worth $19.1M. The position accounts for 0.56% of the portfolio, ranked #24.

Wedbush Securities first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Wedbush Securities held 88,002 shares of AbbVie worth $19.1M as of Q1 2026.
  • Wedbush Securities bought 7,465 AbbVie shares in Q1 2026, an estimated $1.66M.
  • AbbVie made up 0.56% of Wedbush Securities's portfolio in Q1 2026, its #24 holding.
  • Wedbush Securities first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Wedbush Securities's 13F filing for Q1 2026, filed 21 Apr 2026.